Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Gonzalez, R; Urbano, J; Solana, MJ; Hervias, M; Pita, A; Perez, R; Alvarez, R; Teigell, E; Gil-Jaurena, JM; Zamorano, J; Sobrino, A; Lopez-Herce, J.

Microcirculatory Differences in Children With Congenital Heart Disease According to Cyanosis and Age

Frontiers In Pediatrics. 2019; 7: Nº de citas: 7 [doi:10.3389/fped.2019.00264]

Conteduca, V; Castro, E; Wetterskog, D; Scarpi, E; Jayaram, A; Romero-Laorden, N; Olmos, D; Gurioli, G; Lolli, C; Sacz, MI; Puente, J; Schepisi, G; Salvi, S; Wingate, A; Medina, A; Querol-Ninerola, R; Marin-Aguilera, M; Arranz, JA; Fornarini, G; Basso, U; Mellado, B; Gonzalez-Billalabeitia, E; Attard, G; De Giorgi, U.

Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer

EUROPEAN JOURNAL OF CANCER. 2019; 116: 158-168 Nº de citas: 27 [doi:10.1016/j.ejca.2019.05.007]

Sestak, I; Martin, M; Dubsky, P; Kronenwett, R; Rojo, F; Cuzick, J; Filipits, M; Ruiz, A; Gradishar, W; Soliman, H; Schwartzberg, L; Buus, R; Hlauschek, D; Rodriguez-Lescure, A; Gnant, M.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

BREAST CANCER RESEARCH AND TREATMENT. 2019; 176(2): 377-386 Nº de citas: 71 [doi:10.1007/s10549-019-05226-8]

Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; Alfonso, PG; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BMC CANCER. 2019; 19: Nº de citas: 13 [doi:10.1186/s12885-019-5753-7]

Picornell, AC; Echavarria, I; Alvarez, E; Lopez-Tarruella, S; Jerez, Y; Hoadley, K; Parker, JS; del Monte-Millan, M; Ramos-Medina, R; Gayarre, J; Ocana, I; Cebollero, M; Massarrah, T; Moreno, F; Saenz, JAG; Moreno, HG; Ballesteros, A; Borrego, MR; Perou, CM; Martin, M.

Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

BMC GENOMICS. 2019; 20: Nº de citas: 40 [doi:10.1186/s12864-019-5849-0]

Cortes, J; Andre, F; Goncalves, A; Kummel, S; Martin, M; Schmid, P; Schuetz, F; Swain, SM; Easton, V; Pollex, E; Deurloo, R; Dent, R.

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer

Future Oncology. 2019; 15(17): 1951-1961 Nº de citas: 64 [doi:10.2217/fon-2019-0059]

Domine, M; Massuti, B; Puente, J; Calles, A; Esteban, E; Triguboff, E; Afonzo, YS; Girones, R; Aparisi, F; Oramas, J.

Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

ADVANCES IN THERAPY. 2019; 36(6): 1497-1508 Nº de citas: 4 [doi:10.1007/s12325-019-00931-8]

Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Munoz-Unceta, N; Jimeno, R; Lopez, C.

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2019; 83(6): 1175-1181 Nº de citas: 49 [doi:10.1007/s00280-019-03820-7]

Mulder, FI; Candeloro, M; Kamphuisen, PW; Di Nisio, M; Bossuyt, PM; Guman, N; Smit, K; Buller, HR; van Es, N; Abdel-Razeq, H; Ades, S; Ayappan, SR; Borchmann, S; Cella, CA; Fankhauser, CD; Ferroni, P; Fuentes, HE; Kruger, S; Lim, SH; Lubberts, S; Lustig, DB; Mansfield, AS; Martin, AJM; Noble, S; Panizo, E; Papaxoinis, G; Park, K; Patel, JN; Posch, F; Ramos, JD; Roselli, M; Santi, R; Sohal, D; Srikanthan, A; Tafur, AJ; Terbuch, A; Thomas, M; Vathiotis, O; Wang, R; Zahir, MN; CAT-prediction Collaborators.

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

HAEMATOLOGICA. 2019; 104(6): 1277-1287 Nº de citas: 233 [doi:10.3324/haematol.2018.209114]

Perez, EA; de Haas, SL; Eiermann, W; Barrios, CH; Toi, M; Im, YH; Conte, PF; Martin, M; Pienkowski, T; Pivot, XB; Burris, HA; Stanzel, S; Patre, M; Ellis, PA.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC CANCER. 2019; 19: Nº de citas: 51 [doi:10.1186/s12885-019-5687-0]

Perez-Ruiz, E; Minute, L; Otano, I; Alvarez, M; Ochoa, MC; Belsue, V; de Andrea, C; Rodriguez-Ruiz, ME; Perez-Gracia, JL; Marquez-Rodas, I; Llacer, C; Alvarez, M; de Luque, V; Molina, C; Teijeira, A; Berraondo, P; Melero, I.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

NATURE. 2019; 569(7756): 428 Nº de citas: 371 [doi:10.1038/s41586-019-1162-y]

Moreno, F; Gayarre, J; Lopez-Tarruella, S; del Monte-Millan, M; Picornell, AC; Alvarez, E; Garcia-Saenz, JA; Jerez, Y; Marquez-Rodas, I; Echavarria, I; Palomero, M; Bueno, C; Bodi, AMA; Munoz, MS; del Val, RG; Bueno, O; Cebollero-Presmanes, M; Ocana, I; Arias, A; Romero, P; Massarrah, T; Ramos-Medina, R; Martin, M.

Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study

Jco Precision Oncology. 2019; 3: Nº de citas: 13 [doi:10.1200/PO.18.00263]

Trilla-Fuertes, L; Gamez-Pozo, A; Prado-Vazquez, G; Zapater-Moros, A; Diaz-Almiron, M; Fortes, C; Ferrer-Gomez, M; Lopez-Vacas, R; Blanco, VP; Marquez-Rodas, I; Soria, A; Vara, JAF; Espinosa, E.

Melanoma proteomics suggests functional differences related to mutational status

Scientific Reports. 2019; 9: Nº de citas: 11 [doi:10.1038/s41598-019-43512-z]

Garcia-Alfonso, P; Torres, G; Garcia, G; Gallego, I; Ortega, L; Sandoval, C; Munoz, A; Lloansi, A.

FOLFOXIRI plus biologics in advanced colorectal cancer

EXPERT OPINION ON BIOLOGICAL THERAPY. 2019; 19(5): 411-422 Nº de citas: 7 [doi:10.1080/14712598.2019.1595580]

Aznar, MA; Planelles, L; Perez-Olivares, M; Molina, C; Garasa, S; Etxeberria, I; Perez, G; Rodriguez, I; Bolanos, E; Lopez-Casas, P; Rodriguez-Ruiz, ME; Perez-Gracia, JL; Marquez-Rodas, I; Teijeira, A; Quintero, M; Melero, I.

Immunotherapeutic effects of intratumoral nanoplexed poly I:C

Journal for ImmunoTherapy of Cancer. 2019; 7: Nº de citas: 115 [doi:10.1186/s40425-019-0568-2]

Santos, C; Azuara, D; Vieitez, JM; Paez, D; Falco, E; Elez, E; Lopez-Lopez, C; Valladares, M; Robles-Diaz, L; Garcia-Alfonso, P; Buges, C; Duran, G; Salud, A; Navarro, V; Capella, G; Aranda, E; Salazar, R; de Mena, IR; Rodriguez, S.

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

ANNALS OF ONCOLOGY. 2019; 30(5): 796-803 Nº de citas: 17 [doi:10.1093/annonc/mdz082]

Macarulla, T; Carrato, A; Diaz, R; Garcia, A; Laquente, B; Sastre, J; Alvarez, R; Munoz, A; Hidalgo, M.

Management and supportive treatment of frail patients with metastatic pancreatic cancer

Journal of Geriatric Oncology. 2019; 10(3): 398-404 Nº de citas: 6 [doi:10.1016/j.jgo.2018.06.005]

Colomer, R; Saura, C; Sanchez-Rovira, P; Pascual, T; Rubio, IT; Burgues, O; Marcos, L; Rodriguez, CA; Martin, M; Lluch, A.

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

ONCOLOGIST. 2019; 24(5): 603-611 Nº de citas: 51 [doi:10.1634/theoncologist.2018-0228]